Overview of Enterogram

Enterogram is a pharmaceutical preparation marketed specifically as an intestinal anti-infective agent, containing the active substance Colistin Sulfate. Its core function is to address bacterial pathogens through localized, highly concentrated activity within the gastrointestinal system, which is the primary differentiating factor in its formulation compared to systemic antibiotics.

Quick Facts

Property	Description
Active ingredient	Colistin Sulfate (Polymyxin E)
Form	Oral dosage form (Tablets or Capsules)
Pharmacological class	Polypeptide Antibiotic / Polymyxin Class
Common use	Localized elimination of pathogenic gut bacteria
Origin	Derived from the bacterium Paenibacillus colistinus

1. What Type of Medicine is Enterogram? (Identity and Classification)

Enterogram belongs to the Polymyxin class of anti-infective agents, whose active component is the substance Colistin Sulfate. This classification places it within a distinct group of polypeptide antibiotics. The structure of Colistin is a cyclic polypeptide, which gives it a unique bactericidal mechanism. Unlike many newer agents, this class is clinically recognized for its effectiveness against specific Gram-negative organisms, particularly when resistance to alternative antimicrobial treatments is documented. This distinct positioning makes it a crucial, prescription-only option in targeted clinical scenarios.

2. Composition, Origin, and Form (Substance and Physical Nature)

The active substance in Enterogram is Colistin Sulfate (Polymyxin E), which is a derived compound, originally isolated from cultures of the bacterium Paenibacillus colistinus. For its specific purpose as a treatment acting locally on the intestinal environment, the preparation is typically delivered in an oral dosage form, commonly as tablets or capsules. The drug is formulated specifically to remain largely unabsorbed from the gastrointestinal tract following oral administration. This indicates that the medication is designed to provide maximum therapeutic effect within the intestines rather than circulating throughout the body, reinforcing its status as a localized therapeutic option.

3. General Purpose of Enterogram as an Anti-infective (High-Level Benefit)

The general purpose of Enterogram is the localized elimination of pathogenic bacteria within the gastrointestinal tract. The Colistin Sulfate achieves this through a bactericidal mode of action, meaning it directly kills susceptible bacterial cells by physically disrupting their outer protective membrane. Colistin is recognized as a critically important antimicrobial, a status that confirms its significant value in managing specific drug-resistant pathogens. This targeted action helps to rapidly clear the proliferation of unwanted microbial populations in the intestines, serving as an effective means of local anti-infective control, particularly in scenarios requiring suppression of colonic flora.

Regulatory References

What side effects are possible with Enterogram?

Possible Side Effects and Safety Information

The official safety profile of Enterogram (oral Colistin Sulfate) is structured around potential adverse reactions that affect various organ systems, as documented in regulatory sources. Given the drug's design for localized action in the gut, the risk profile is primarily weighted toward gastrointestinal effects, while also including warnings for systemic toxicities inherent to the polymyxin class.

Adverse Reactions by System-Organ Class

Adverse reactions are officially categorized primarily into the following systems:

Gastrointestinal Disorders: Reactions localized to the gut are commonly reported, including upset stomach, severe stomach pain, and diarrhea. As with most antibacterials, Clostridioides difficile-associated diarrhea (CDAD) is a documented risk.
Nervous System Disorders: Potential neurotoxicity has been documented, manifesting as transient neurological disturbances such as numbness or tingling (paresthesia) of the extremities, mouth, or tongue, and sometimes slurred speech or vertigo.
Renal and Urinary Disorders: The potential for Acute Kidney Injury (AKI) and renal dysfunction (nephrotoxicity) is cited in regulatory warnings for the polymyxin class, a serious concern that is typically dose-dependent.
Immune System Disorders: Official labels warn of the possibility of hypersensitivity reactions, including anaphylaxis.

Serious Safety Considerations

The most serious reactions explicitly highlighted in regulatory warnings include nephrotoxicity, neurotoxicity (which may involve seizures or respiratory arrest), and CDAD. Safety notes also address specific populations:

Impaired Renal Function: Caution is advised, as impaired kidney function can increase the possibility of systemic toxicity.
Pregnancy and Lactation: Official information indicates that the substance may cross the placenta and is excreted in human breast milk, necessitating caution. Prolonged use carries the risk of overgrowth of non-susceptible organisms.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based on official government regulatory documents detailing the potential systemic effects of Colistin Sulfate if the drug reaches high serum levels, typically due to excessive dosage or failure to adjust for impaired renal function.

Documented Manifestations and Severe Outcomes

Overdose manifestations are primarily characterized by neurotoxicity and nephrotoxicity. Officially documented signs include:

Neurological: Paresthesia (tingling around the mouth), slurred speech, dizziness, vertigo, and confusion.
Renal: Signs of impaired renal function, such as diminished urine output.

The most severe outcome is neuromuscular blockade, which can lead to profound muscle weakness and potentially apnea (respiratory arrest).

Required Emergency Action

Immediate medical attention is required for any suspected overdose or if severe symptoms, such as apnea or severe muscle weakness, occur. Patients or caregivers must contact emergency services or a poison control center immediately.

Management is symptomatic and supportive, as no specific antidote is available. If signs of impaired renal function appear, the medication must be discontinued immediately, and intensive medical monitoring for respiratory and renal status is necessary.

Therapeutic Uses of Enterogram

What Enterogram Treats: Main Uses and Benefits

Enterogram (oral Colistin Sulfate) is commonly used to manage conditions and clinical scenarios requiring localized anti-infective support within the gastrointestinal tract, offering symptomatic relief and supportive risk-management benefits. Colistin Sulfate is categorized as an Intestinal Anti-infective Agent (A07A). The drug is commonly used across domains where short-term symptom management is appropriate.

Clinical Relevance and Indications

The medication is applied across domains where additional symptomatic support is needed for acute and disruptive symptoms like diarrhea and dysentery, when caused by susceptible Gram-Negative Bacilli (GNB). The use of the medication helps address symptom clusters that may become intense or disruptive by addressing the bacterial presence. This action contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes by easing distress.

Enterogram is commonly used in specialized clinical settings, specifically for preoperative bowel preparation before certain surgical procedures (e.g., colorectal surgery) and in Intensive Care Unit (ICU) protocols for Selective Digestive Tract Decontamination (SDD). In these scenarios where additional management of discomfort is required, the product provides support that helps ease the overall symptom burden of potential secondary infections by controlling the presence of Gram-Negative bacteria in the digestive tract.

“The primary role of oral Colistin Sulfate is to provide targeted, localized anti-infective support to the intestinal environment, used for addressing acute symptoms and supportive risk-management.”

Quick Fact: Relief for Infectious Diarrhea and Prophylactic Risk Reduction

Regulatory References

KEGG DRUG Classification

Eligibility and Restrictions for Use

Who Can and Cannot Use Enterogram?

Enterogram (oral Colistin Sulfate) eligibility is strictly defined by government regulatory documents, based on known contraindications and population-specific limitations.

Populations Who Must Not Use Enterogram (Contraindicated)

Official labeling specifies absolute prohibitions for certain patient groups:

Hypersensitivity: Individuals with a history of allergy to Colistin Sulfate or any other polymyxin antibiotic are strictly contraindicated.
Specific Conditions: Patients diagnosed with Myasthenia Gravis or Porphyria are formally prohibited from using the medicine.

Populations with Restrictions or Conditional Use

Use is not recommended or requires caution in the following groups, as established by regulatory authorities:

Age and Weight: Use is generally not recommended in children under 12 years of age or those weighing less than 40 kg.
Organ Function: Patients with pre-existing or severe renal impairment require the greatest caution and close monitoring.
Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding, as the substance is known to cross the placental barrier and be excreted in human milk.

The eligibility structure is based on formal regulatory classifications, ensuring that the medicine is reserved for generally healthy adults and older pediatric patients for whom the risk profile for localized use is established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Enterogram (Oral Colistin Sulfate) is primarily formulated as a localized intestinal anti-infective, and its official interaction profile is structured around its limited systemic absorption and activity within the gut. Regulatory documentation identifies specific constraints related to pharmacodynamic antagonism and metabolic interference that may occur with co-administered products.

Official Interaction Statements

Interacting Product Category	Interaction Pattern and Regulatory Constraint
Live Oral Bacterial Vaccines (e.g., Cholera Vaccine)	Contraindicated Combination: Co-administration is formally restricted due to pharmacodynamic antagonism. The anti-infective action of Enterogram may counteract the intended therapeutic effect of the live vaccine strain.
Flora-Dependent Cleansing Agents (e.g., Sodium Picosulfate Preparations)	Reduced Efficacy: Enterogram alters the colonic bacterial flora required to convert the cleansing agent into its pharmacologically active form, leading to metabolic interference and reduced effect.

Administration Requirements

Official labeling includes a mandatory timing rule to mitigate antagonism with Live Oral Bacterial Vaccines, requiring that administration of Enterogram be avoided within 14 days prior to vaccination. Due to the oral product’s poor absorption, regulatory information does not typically document clinically relevant systemic pharmacokinetic interactions (such as CYP enzyme or transporter effects).

Mechanism of Action

How Enterogram Works

Enterogram acts locally within the gastrointestinal lumen via specific non-systemic mechanisms. Its mechanism involves direct interaction with biological targets and signaling pathways confined to the intestinal surface.

Luminal Toxin Binding

This action involves the high-affinity binding of bacterial toxins and other microbial components that function as signaling molecules within the intestinal lumen. This binding interaction results in the neutralization of these substances within the lumen, consequently altering their availability at the mucosal surface and influencing epithelial signaling.

Intestinal Barrier Modulation

Enterogram influences physiological responses by affecting processes essential for maintaining mucosal barrier characteristics. The interception of microbial components modifies the downstream activity of various inflammatory mediators, which subsequently influences the stability and maintenance of intestinal lining characteristics.

Local Pathway Influence

The non-absorbed components of Enterogram modify specific early molecular steps that activate inflammatory or permeability signaling sequences. This modulation results in an altered pattern of pathway activity within the intestinal mucosa, achieving a targeted adjustment of local physiological processes.

Dosage and Administration Information

How to Use Enterogram: Official Administration and Dosing

The correct use of Enterogram (oral Colistin Sulfate) is strictly governed by its designation as an intestinal anti-infective agent, which is designed for localized action within the gut with minimal systemic absorption.

Official Administration and Scheduling

Instruction	Official Rule from Regulatory Documents
Route of Administration	The approved route is Oral (by mouth).
Dosage Forms	Typically provided as Tablets, Capsules, or Oral Suspension (when reconstituted from powder).
Dosing Schedule	The total daily dose is divided and administered multiple times per day (e.g., two to four times daily) to maintain continuous local concentration in the intestine.
Treatment Duration	Use is defined as short-term treatment, generally limited to a specific duration (e.g., often not exceeding 7 to 10 days) as specified in the official prescribing information.

Use Instructions and Special Populations

Administration must strictly follow the conditions outlined in the product's official labeling, such as instructions on taking the dose with or without food. If the product is an oral powder, it must be reconstituted (mixed with liquid) just prior to use or within the manufacturer-specified short stability period.

For pediatric use, dosing is determined based on the child's body weight, following the official regimens detailed in the prescribing information. Because the oral formulation is minimally absorbed, dose adjustments for patients with renal or hepatic impairment are typically not specified in the labels for intestinal use, differentiating it from the use of its systemic counterparts.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Evidence for use in Schizophrenia

Research was studied for adults with conditions characterized by episodic manifestations like Schizophrenia. Studies exploring short-term symptom changes typically used controlled trial designs (Randomized Controlled Trials or RCTs), measuring changes in standardized scales, and research examined patterns related to relapse over time. Findings describe measured changes on symptom intensity scales that, over short-term defined time intervals, were statistically separated from the observations in the placebo groups. The long-term outcomes and duration of symptom evolution are not well characterized by the existing evidence. Follow-up durations were limited in the primary controlled studies.

Evidence for use in Bipolar Disorder (Manic or Mixed Episodes)

The agent was studied for its role in conditions involving periods of heightened symptoms, specifically acute manic or mixed episodes in adults. Research designs included short-term RCTs, where the agent was observed in studies either alone or added to another medication. The short-term research reported measured changes on the mania rating scales that were statistically separated from the comparison groups over three-week periods. It is not yet clear whether the observed patterns extend across the full course of the condition. There is limited information for long-term outcomes, as the trials typically focused only on the acute episode.

Evidence in Special Populations and Areas where Research is Ongoing

Research has explored the agent in children and adolescents for Irritability Associated with Autistic Disorder, using short-term RCTs to examine outcomes related to episodic or acute changes. However, long-term outcomes in this age group are not fully established. For most indications, follow-up durations were limited across many studies, meaning long-term effects are not fully established. Data for certain groups, such as older adults, pregnant individuals, or those with numerous comorbid conditions, remain insufficient. Findings describe group patterns, not personal outcomes, and certainty remains low regarding individual predictions.

Key Studies & References

Clinical practice guideline for the treatment of schizophrenia

Frequently Asked Questions (FAQ)

Common questions about Enterogram (FAQ)

Q: Is Enterogram a laxative, a probiotic, or something else?

Official regulatory documents classify Enterogram as a polypeptide antibiotic, which is a type of anti-infective medicine. This means its primary action is focused on eliminating pathogenic bacteria within the gut. It is therefore not categorized as a laxative or a probiotic.

Q: What are the most common side effects people report for Enterogram?

According to the official product information, the most frequently reported adverse reactions are often localized to the digestive system, such as upset stomach and diarrhea. Some neurological effects, like numbness or tingling (paresthesia), are also commonly reported.

Q: Are there any specific foods that should be avoided when using Enterogram?

The official patient information leaflet generally states that Enterogram can be taken with or without food, as adherence to the dosing schedule is key. There are typically no specific food restrictions listed in the regulatory warnings for this medication.

Q: Does the time of day matter when taking Enterogram?

Regulatory guidance indicates that the total daily dose is divided and taken multiple times per day to ensure continuous local concentration in the intestine. The medication should be taken according to the specific dosing schedule prescribed to help maintain concentration.

Q: Can Enterogram be used by people who are pregnant or trying to conceive?

Official information states that the medicine may be used during pregnancy only if the potential benefit is judged to outweigh the potential risk. The active substance is known to be excreted in human breast milk, which requires caution if considering use while breastfeeding.

Q: Is Enterogram considered suitable for use in elderly or older patients?

Caution is advised for the elderly population, primarily because a natural decline in kidney function with advanced age must be considered. Regulatory documents state that monitoring and dosage adjustment may be needed if renal impairment is present.

Q: Is Enterogram safe for people who have pre-existing kidney or liver issues?

Official warnings highlight the need for extreme caution and close monitoring for individuals with pre-existing kidney impairment. A person's complete health history should be reviewed, particularly regarding renal function. The need for adjustment with liver impairment is not typically specified for the oral formulation.

Q: Does Enterogram affect a person's ability to drive or operate machinery?

Patients are formally warned not to drive or operate hazardous machinery due to the possibility of transient neurological disturbances. These effects, which are listed in the safety information, include dizziness and vertigo.

Q: Can the Enterogram tablet or capsule be crushed, split, or chewed?

Instructions for manipulating solid dosage forms depend on the specific formulation, such as whether it is enteric-coated. While some guidance may allow for crushing or dispersion, this information should be checked against the specific product label or patient information leaflet.

Q: What off-label uses for Enterogram have been investigated in research studies?

Regulatory labels strictly address only the approved uses of the medicine. Any information found regarding investigational use in conditions other than the approved indications relates to ongoing research and is not approved by regulatory bodies for clinical use.

Q: Do the side effects of Enterogram lessen or go away over time?

Official patient information describes some common neurological side effects, such as tingling or dizziness, as transient in nature. This suggests that these effects may lessen or resolve as the course of treatment continues.

Q: Are there any long-term side effects documented for Enterogram?

Studies and official information indicate that the follow-up periods in the primary controlled trials for this medicine were typically limited. This means that the long-term effects are not fully established by the existing research evidence.

Q: Can Enterogram be taken with common over-the-counter pain relievers?

Due to the drug's poor absorption into the bloodstream, regulatory labels generally do not document clinically relevant systemic interactions with pain relievers. However, potential local or general drug class warnings should always be considered.

Q: Does Enterogram interact with common vitamins or dietary supplements?

Official safety documentation does not typically include information on specific systemic interactions with vitamins or common dietary supplements. Information about all vitamins and supplements being used should be reviewed to understand potential interactions.

Q: Does Enterogram interact with oral contraceptives or birth control pills?

Because Enterogram is an antibiotic, it carries the general class caution that it may potentially reduce the efficacy of hormonal birth control. This possibility is typically discussed with a healthcare professional, especially regarding the need for alternative contraception.

Q: What might happen if I stop taking Enterogram suddenly?

Stopping the antibiotic prematurely carries the risk of overgrowth of non-susceptible organisms in the gut. Furthermore, it may prevent the medicine from fully clearing the initial infection, which could lead to recurrence.

Q: What is the general guidance if a dose of Enterogram is missed?

The product label usually advises taking a missed dose as soon as it is remembered. If it is nearly time for the next dose, the label usually advises skipping the missed dose to avoid taking doses too closely.

Q: Where can I find the official regulatory prescribing information for Enterogram?

The full, detailed regulatory prescribing information is publicly available through official government databases. These sources include the FDA DailyMed database or the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).

Q: Is Enterogram known or marketed by any other trade or generic name?

The active ingredient, which is Colistin Sulfate, is a common therapeutic substance. As is typical for pharmaceuticals, this active ingredient may be marketed globally under various different trade names.

Q: Are there any reports of Enterogram affecting the results of routine blood tests?

Official warnings emphasize the possibility of nephrotoxicity (kidney damage), which requires frequent monitoring of renal function. This monitoring involves blood tests to assess key kidney indicators like BUN and creatinine.

Q: What is the recommended course of action if symptoms do not improve while on Enterogram?

Regulatory documents state that if symptoms persist or worsen, a lack of response usually leads to a re-evaluation of the condition. This is because non-improvement may be due to an overgrowth of non-susceptible organisms.

Q: Is there a concern that Enterogram could be habit-forming or addictive?

There are no warnings or official reports in regulatory documents indicating that the active substance, Colistin Sulfate, carries a risk of addiction, dependency, or habit-forming behavior.

Q: Does Enterogram commonly cause symptoms like tiredness or drowsiness?

Dizziness and drowsiness are reported side effects, and official warnings advise patients about potential impairment of alertness. Furthermore, a serious safety consideration, kidney issues, can also cause a feeling of unusual tiredness.

Q: What are the general signs or symptoms of taking too much Enterogram?

Symptoms associated with taking too much Enterogram can include confusion, dizziness, loss of balance/coordination, severe numbness/tingling, problems with speech, weak/shallow breathing, or loss of consciousness. These signs are highlighted in the overdose section of the official label.

Q: Can Enterogram affect a person's mood, anxiety, or mental health?

Regulatory documents list neurological side effects such as slurred speech and vertigo, which are related to the nervous system. However, the official documents do not specifically detail adverse effects on general mood, anxiety, or other mental health conditions.

Q: Can I take Enterogram if I have a known intolerance to lactose or gluten, and does it contain sugar or sodium?

The presence of excipients (inactive ingredients) such as lactose, sugar, sodium, or gluten is specific to the formulation chosen by the manufacturer. This information should be checked against the product label for suitability with known intolerances.

How should Enterogram be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal rules apply to the contrast agents and related pharmaceuticals used for the Enterogram procedure, as defined by regulatory documents (e.g., FDA, EMA).

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature (20 C to 25 C). Do not freeze or expose to excessive heat.
Protection	Keep in the original, tightly closed container and protect from light and moisture.
Stability	Any solution that is diluted or prepared must be used immediately or within a strict, short-term in-use period.
Child Safety	The product must be stored out of the reach of children.
Disposal	Do not dispose of unused or expired product in household trash or down the drain. Follow official pharmaceutical take-back programs or local regulated waste procedures. Used syringes and needles must be placed in designated sharps containers.

Enterogram